Efficacy of VOYDEYA® (danicopan)
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
In the superiority Phase 3 ALPHA trial, the safety and efficacy of VOYDEYA® was evaluated based on 12-week data from 63 adult patients with Paroxysmal nocturnal hemoglobinuria (PNH) who received VOYDEYA® or placebo at the recommended dosing regimen as add-on therapy to ULTOMIRIS® (ravulizumab) or SOLIRIS® (eculizumab).1

Visit the Study Design page to get more information on the study design of the ALPHA trial.
ALPHA Study Design
Primary endpoint met: Patients who received VOYDEYA® achieved a clinically meaningful, statistically significant increase in mean Hb levels from baseline compared with placebo at 12 weeks (change in least squares mean [LSM] Hb: 2.94 [95% CI 2.52 to 3.36] g/dL versus 0.50 [95% CI -0.13 to 1.12] g/dL; p<0.0001).*†1,2
*Based on MMRM test.1,2

†A change in Hb of ≥2 g/dL is considered clinically meaningful.1
of patients treated with VOYDEYA® were transfusion-free* over 12 weeks, compared with 38% (8/21) of patients treated with placebo (p=0.0004).1
of patients receiving VOYDEYA® were transfusion free* at Week 72 compared with 8.8% (5/57; VOYDEYA® group) and 17.2% (5/29; placebo group) in the 24 weeks prior to screening.3
of patients treated with VOYDEYA® had a Hb increases of ≥2 g/dL at 12 weeks in the absence of transfusion compared with 0% (0/21) of patients treated with placebo (p<0.0001),1 a similar treatment effect was observed over 72 weeks.3
Patients treated with VOYDEYA® had significantly reduced absolute reticulocyte count (ARC) from baseline at Week 12 compared with placebo (–83.8×109/L [95% CI: –101.6 to –65.9] vs 3.5×109/L [95% CI: –21.9 to 28.8]; p<0.0001) and levels were maintained to Week 72.3
*Patients who did not receive a transfusion and did not meet the protocol-specified guidelines for transfusion through the 12-week treatment period were considered to have been transfusion free.1

†A change in haemoglobin of ≥2 g/dL is considered clinically meaningful.1
Adding VOYDEYA® to ULTOMIRIS® or SOLIRIS® resulted in significantly improved FACIT-Fatigue scores* at Week 12 compared with placebo (8.0 points [95% CI: 5.7 to 10.2] vs 1.9 points [95% CI: –1.3 to 5.0]; p=0.0021).1

Mean FACIT-Fatigue scores observed with VOYDEYA® at Week 12 were comparable to those reported in the general population and were sustained to Week 72.3
*Fatigue was self-assessed using the FACIT-Fatigue scale.5,6 A change in FACIT-Fatigue score of ≥5 points is considered clinically meaningful in PNH.5

†Mean FACIT-Fatigue score for the general population was determined through assessment of 2,426 adults (n=1,074 males; n=1,352 females; mean age [SD]: 49.8 [17.4] years) in Germany between March 2015 and May 2015.6
IVH control (as evaluated by lactose dehydrogenase [LDH] levels of <1.5xULN*) was maintained at Week 72 in both arms, through long-term control of terminal complement activity via C5 inhibition.3
  • 86% (6/7) of events were mild to moderate in severity and all resolved rapidly without trial discontinuation, dose adjustment or need for transfusion.3
  • One event was associated with LDH ≥2x ULN (2.2x ULN) and decreased Hb, which was temporarily associated with COVID-19 infection.3
*ULN for LDH levels in clinical trials of ULTOMIRIS® in PNH was taken to be 246 U/L.7,8
image
VOYDEYA® was well-tolerated over 12 weeks in the clinical trial and in long-term follow up to Week 721-3
Find out more by visiting the VOYDEYA® safety page below.
Safety of VOYDEYA®

Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion,
AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/
ARC, absolute reticulocyte count; C5, complement component 5; CI, confidence interval; EVH, extravascular haemolysis; FACIT, Functional Assessment of Chronic Illness Therapy; IVH, intravascular haemolysis; LDH, lactate dehydrogenase; LSM, least squares mean; PNH, paroxysmal nocturnal haemoglobinuria; SD, standard deviation; SE, standard error; ULN, upper limit of normal; Hb, haemoglobin.
Lee JW, et al.Lee JW, et al. Addition of Danicopan to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria and Clinically Significant Extravascular Haemolysis (ALPHA): a Double-blind, Randomised, Phase 3 Trial. The Lancet Haematology. 2023;10:e955 – e965. VOYDEYA® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/voydeya-epar-product-information_en.pdf. Last accessed November 2025. Kulasekararaj A, et al. Long-term Efficacy and Safety of Danicopan as Add-on Therapy to Ravulizumab or Eculizumab in PNH with Significant EVH. Blood. 2025;145(8):811–822. Kulasekararaj A, et al. Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH Blood 2024 1-45 (v1.0) 2024. Piatek CI et al. Poster presented at the 65th ASH Annual Meeting and Exposition; 9–12 December 2023; San Diego, CA. Abstract 1346. Schrezenmeier H, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 2014; 922-929. Montan I et al. General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Elsevier Inc. 2018. Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs Eculizumab in C5-Inhibitor–Experienced Adult Patients with PNH: the 302 study. Blood. 2019;133(6):540–549. Lee JW, et al. Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: the 301 Study. Blood. 2019;6(133):530–539.